otovio

Suzhou Otovia Therapeutics Co., incubated and established by the Fosun Pharma New Drug Fund in January 2022, is an innovative biotechnology company focused on inner ear hearing loss-related diseases. Leveraging five world-leading platforms, including dual-AAV gene delivery, gene editing, and organoids, the company develops gene delivery, gene editing, and inner ear hair cell regeneration drugs targeting sensorineural hearing loss.